Mutational activation of KRAS is a common oncogenic event in lung cancer and other epithelial cancer types.Efforts to develop therapies that counteract the oncogenic effects of mutant KRAS have been largely unsuccessf...Mutational activation of KRAS is a common oncogenic event in lung cancer and other epithelial cancer types.Efforts to develop therapies that counteract the oncogenic effects of mutant KRAS have been largely unsuccessful,and cancers driven by mutant KRAS remain among the most refractory to available treatments.Studies undertaken over the past decades have produced a wealth of information regarding the clinical relevance of KRAS mutations in lung cancer.Mutant Kras-driven mouse models of cancer,together with cellular and molecular studies,have provided a deeper appreciation for the complex functions of KRAS in tumorigenesis.However,a much more thorough understanding of these complexities is needed before clinically effective therapies targeting mutant KRAS-driven cancers can be achieved.展开更多
为了增加煤层透气性、提高瓦斯抽采效率,选取七台河矿区进行液态CO2爆破煤层增透工业试验。研究液态CO2爆破过程中主管内高压气体P-T曲线,考察不同地应力下的液态CO2爆破有效影响半径和煤层透气性系数,监测爆破前后瓦斯抽采参数。试验...为了增加煤层透气性、提高瓦斯抽采效率,选取七台河矿区进行液态CO2爆破煤层增透工业试验。研究液态CO2爆破过程中主管内高压气体P-T曲线,考察不同地应力下的液态CO2爆破有效影响半径和煤层透气性系数,监测爆破前后瓦斯抽采参数。试验结果表明:采用压缩气体与水蒸气容器爆破方法计算液态CO2爆破的当量为180 g TNT;爆破后瓦斯抽采浓度提高3.16倍,瓦斯抽采混合流量提高1.71倍;煤层液态CO2爆破有效影响半径随地应力的增加近线性减小,随爆破压力的增加非线性增加,确定液态CO2爆破时最佳爆破压力范围160-280 MPa;爆破前后对比,煤层透气性系数提升17.49-22.76倍。井下煤层液态CO2爆破技术的实施,有助于降低爆破成本、提高增透效果和瓦斯抽采利用率。展开更多
目的:分析局限期小细胞肺癌根治术后辅助放疗(postoperative radiotherapy,PORT)的作用。方法:回顾性分析美国监测、流行病学和最终结果(surveillance,epidemiology,and end results,SEER)数据库中2000年至2016年915例接受手术治疗的局...目的:分析局限期小细胞肺癌根治术后辅助放疗(postoperative radiotherapy,PORT)的作用。方法:回顾性分析美国监测、流行病学和最终结果(surveillance,epidemiology,and end results,SEER)数据库中2000年至2016年915例接受手术治疗的局限期小细胞肺癌患者临床资料,通过对PORT(+)组及PORT(-)组资料应用倾向评分匹配法(propensity score matching,PSM)来均衡组间协变量差异,采用Kaplan-Meier法及log-rank检验进行生存分析,比较2组患者的总生存率(overall survival,OS)和肺癌特异性生存率(lung cancer specific survival,LCSS),分析术后放疗的作用及获益人群。结果:全组中位OS与LCSS分别为31个月和37个月;在进行倾向评分匹配前后,PORT(+)及PORT(-)组的OS及LCSS均无统计学差异。亚组分析显示所有N分期的OS和LCSS均无差异(N0:中位OS 61个月vs.62个月,P=0.838;N1:中位OS 22个月vs.20个月,P=0.735;N2:中位OS19个月vs.16个月,P=0.254)。对淋巴结比率(lymph node ratio,LNR)亚组分析显示,当LNR大于50%时,PORT(+)组存在OS的获益(HR=0.57,95%CI=0.35~0.93;P=0.024),在LCSS上也存在明显获益(HR=0.57,95%CI 0.34~0.95;P=0.030)。多因素分析显示患者年龄、手术方式、LNR、T分期、N分期是局限期小细胞肺癌术后生存率独立的预后影响因素。结论:术后放疗与N0、N1和N2患者的生存率没有关系,与PORT相关的生存获益似乎仅限于LNR为50%或更高的患者。需在其他同类研究和随机对照试验中进一步评估。展开更多
基金supported by the NIH Training GrantT32 GM007175a National Science Foundation Graduate Research Fellowship+1 种基金supportedby a UCSF Academic Senate Research Grantthe Nan Tucker McEvoy Research Fund in Thoracic Oncology
文摘Mutational activation of KRAS is a common oncogenic event in lung cancer and other epithelial cancer types.Efforts to develop therapies that counteract the oncogenic effects of mutant KRAS have been largely unsuccessful,and cancers driven by mutant KRAS remain among the most refractory to available treatments.Studies undertaken over the past decades have produced a wealth of information regarding the clinical relevance of KRAS mutations in lung cancer.Mutant Kras-driven mouse models of cancer,together with cellular and molecular studies,have provided a deeper appreciation for the complex functions of KRAS in tumorigenesis.However,a much more thorough understanding of these complexities is needed before clinically effective therapies targeting mutant KRAS-driven cancers can be achieved.
文摘为了增加煤层透气性、提高瓦斯抽采效率,选取七台河矿区进行液态CO2爆破煤层增透工业试验。研究液态CO2爆破过程中主管内高压气体P-T曲线,考察不同地应力下的液态CO2爆破有效影响半径和煤层透气性系数,监测爆破前后瓦斯抽采参数。试验结果表明:采用压缩气体与水蒸气容器爆破方法计算液态CO2爆破的当量为180 g TNT;爆破后瓦斯抽采浓度提高3.16倍,瓦斯抽采混合流量提高1.71倍;煤层液态CO2爆破有效影响半径随地应力的增加近线性减小,随爆破压力的增加非线性增加,确定液态CO2爆破时最佳爆破压力范围160-280 MPa;爆破前后对比,煤层透气性系数提升17.49-22.76倍。井下煤层液态CO2爆破技术的实施,有助于降低爆破成本、提高增透效果和瓦斯抽采利用率。
文摘目的:分析局限期小细胞肺癌根治术后辅助放疗(postoperative radiotherapy,PORT)的作用。方法:回顾性分析美国监测、流行病学和最终结果(surveillance,epidemiology,and end results,SEER)数据库中2000年至2016年915例接受手术治疗的局限期小细胞肺癌患者临床资料,通过对PORT(+)组及PORT(-)组资料应用倾向评分匹配法(propensity score matching,PSM)来均衡组间协变量差异,采用Kaplan-Meier法及log-rank检验进行生存分析,比较2组患者的总生存率(overall survival,OS)和肺癌特异性生存率(lung cancer specific survival,LCSS),分析术后放疗的作用及获益人群。结果:全组中位OS与LCSS分别为31个月和37个月;在进行倾向评分匹配前后,PORT(+)及PORT(-)组的OS及LCSS均无统计学差异。亚组分析显示所有N分期的OS和LCSS均无差异(N0:中位OS 61个月vs.62个月,P=0.838;N1:中位OS 22个月vs.20个月,P=0.735;N2:中位OS19个月vs.16个月,P=0.254)。对淋巴结比率(lymph node ratio,LNR)亚组分析显示,当LNR大于50%时,PORT(+)组存在OS的获益(HR=0.57,95%CI=0.35~0.93;P=0.024),在LCSS上也存在明显获益(HR=0.57,95%CI 0.34~0.95;P=0.030)。多因素分析显示患者年龄、手术方式、LNR、T分期、N分期是局限期小细胞肺癌术后生存率独立的预后影响因素。结论:术后放疗与N0、N1和N2患者的生存率没有关系,与PORT相关的生存获益似乎仅限于LNR为50%或更高的患者。需在其他同类研究和随机对照试验中进一步评估。